Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Not applicable Interventional

Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction

NCT06333015
View directory record Official record
Conditions
Cataract
Interventions
enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
22 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Dothan, Alabama • Northridge, California • Alexandria, Minnesota + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NCT04048135
View directory record Official record
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03400163
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

NCT00239187
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
E1 and G1
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Chula Vista, California • Clearwater, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

NCT01828593
View directory record Official record
Conditions
HIV-associated Enteropathy
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 25, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Alopecia Areata

NCT04346316
View directory record Official record
Conditions
Alopecia Areata
Interventions
SHR0302
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Brandon, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 25, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

NCT03869684
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
MT-0814, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Peoria, Arizona • Phoenix, Arizona • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 25, 2026, 9:08 AM EDT
Withdrawn Phase 2 Interventional

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00604578
View directory record Official record
Conditions
Asthma, Airway Inflammation, Airflow Obstruction, Airway Hyperactivity
Interventions
Pioglitazone Hydrochloride
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation

NCT00523978
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Arctic Front® Cryoablation Catheter, Flecainide or Sotalol or Propafenone
Device · Drug
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 ED in Steroid-naive Asthmatic Patients

NCT01092143
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont)

NCT00920543
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional

Maribavir for Prevention of CMV After Stem Cell Transplants

NCT00223925
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Maribavir, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 9:08 AM EDT
Not listed Phase 3 Interventional

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

NCT00454389
View directory record Official record
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Belumosudil, Placebo
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 25, 2026, 9:08 AM EDT
Recruiting Not applicable Interventional

Healing, Equity, Advocacy and Respect for Mamas

NCT06273436
View directory record Official record
Conditions
Postpartum Complication
Interventions
H.E.A.R. for Mamas
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
16 Years to 49 Years · Female only
Enrollment
2,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality

NCT07769164
View directory record Official record
Conditions
Sleep Disturbance, Sleep Quality
Interventions
2 mg THC + 2 mg CBN + 2 mg CBG + 10 mg CBD + 1 mg Melatonin, 10 mg THC + 5 mg CBN + 5 mg CBG + 20 mg CBD, 10 mg THC + 20 mg CBN + 5 mg CBG, Stay Asleep Placebo, Fast Asleep Placebo
Dietary Supplement
Lead sponsor
Cannabis Science Innovations, LLC
Industry
Eligibility
21 Years to 55 Years
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 9:08 AM EDT